Treatments which elevate functional glycosylated leptin trasnport factor, for controlling weight and obesity

• US 20050049184A1
• Filed: 09/10/2004
• Published: 03/03/2005
• Est. Priority Date: 08/04/2000
• Status: Abandoned Application

• Current Assignee: Linfo Research Inc.
• Original Assignee: Ronald Gingerich
• Inventors: Gingerich, Ronald, Qian, Hao
• Application Number:
  US10/938,049
• Publication Number:
  US 20050049184A1
• Time in Patent Office: Days
• US Class Current: 514/1.200
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: C07K 16/2869 against hormone receptors for antibodies against neuromediator receptors C07K16/286
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

Methods and compounds for treating obesity and inducing weight loss use a functional, glycosylated leptin transport factor (LTF) polypeptide, referred to as fn/glyLTF. An unstable defective version of the LTF protein, referred to herein as def/LTF, is present in freshly-drawn blood from obese animals or people; it is degraded rapidly in circulating blood. In people with normal body weight, fn/glyLTF stabilizes and protects leptin, a hormone with powerful effects on fat metabolism and body mass. LTF apparently is the same protein previously recognized as a soluble truncated fragment of the obesity receptor (Ob-R) protein, referred to in the prior art as Ob-Re, or sOb-R. In humans with normal body weight, fn/glyLYF has a weight of about 145 kD, compared to a polypeptide-only weight of about 93 kD. defLTF has a substantially lower molecular weight, and tests using deglycosylating enzymes indicate that it is not glycosylated to the same level as fn/glyLTF. Treatment methods include: (1) elevating concentrations of fn/glyLTF in circulating blood, by means such as intravenous injection or sustained-release implants, or by gene therapy; (2) suppressing enzymatic deglycosylation in circulating blood, such as by extracorporeal removal of deglycosylating enzymes; and, (3) providing “surrogate” forms of fn/glyLTF. Diagnostic kits are also disclosed, for measuring both fn/glyLTF and def/LTF in animals and people suffering from obesity.

Claims

1. A method for improved pharmacologic control of fat metabolism and body mass in mammals, comprising the step of introducing, into circulating blood of a mammal being treated, a pharmacologic preparation containing glycosylated leptin transport factor (also known as Ob-Re or sOb-R), in a therapeutic quantity which induces weight loss in the mammal being treated.

2. The method of claim 1 wherein the glycosylated leptin transport factor is introduced into the circulating blood by means selected from the group consisting of intravenous injection, intravenous infusion, and intramuscular injection.

3. The method of claim 1 wherein the glycosylated leptin transport factor is introduced into the circulating blood by subcultaneous implantation of a sustained-release device containing glycosylated leptin transport factor.

4. The method of claim 1 wherein the glycosylated leptin transport factor is introduced into the circulating blood by implantation of a device which contains cells that secrete glycosylated leptin transport factor, enclosed within a permeable encapsulating material that prevents an immune rejection response in the body of the mammal being treated.

5. The method of claim 4, wherein the cells that secrete glycosylated leptin transport factor have been genetically engineered to contain at least one exogenous gene which encodes a polypeptide selected from the group consisting of a leptin transport factor, a portion of a leptin transport factor which after glycosylation binds to leptin in circulating blood, and a glycosidase enzyme which adds sugar moieties to a leptin transport factor of polypeptide.

6. The method of claim 1 wherein the glycosylated leptin transport factor is introduced into the circulating blood by means selected from the group consisting of trans-membrane permeation, and oral ingestion of a capsule having an enteric coating that resists digestion by stomach acid.

7. A method of genetic treatment to induce weight loss in a mammal, comprising the following steps:

a. removing, from the mammal, at least one selected cell type which can generate large numbers of progency cells that will be capable of secreting glycosylated proteins;

b. treating the selected cell type with a genetic vector which carries at least one foreign gene which encodes a polypeptide selected from the group consisting of a leptin transport factor, and a portion of a leptin transport factor which, after glycosylation, will bind to leptin in circulating blood;

c. selecting progeny cells which have been genetically transformed, which express the leptin transport factor or portion thereof which is encoded by the foreign gene, and which secrete glycosylated copies of the leptin transport factor or portion thereof;

d. implanting the genetically transformed cells into the mammal being treated.

8. The method of claim 7, wherein the genetic vector also carries at least one foreign gene which encodes a glycosidase enzyme which is known to add sugar moieties to the leptin transport factor polypeptide.

9. A method of extracorporeal blood treatment to induce weight loss in mammals, comprising the following steps:

a. analyzing blood from a mammal suffering from excess weight, to identify at least one blood-borne enzyme which degrades glycosylated leptin transport factor;

b. selecting an antibody preparation which binds to a targeted blood-borne enzyme which degrades glycosylated leptin transport factor;

c. removing blood from the mammal;

d. passing the blood through a device which contains the selected antibody preparation, under conditions which enable the antibody preparation to contact the blood and remove a quantity of the targeted blood-borne enzyme which degrades glycosylated leptin transport factor; and

,

e. returning the blood which has been passed through the device to the mammal being treated.

10-12. -12. (cancelled)